Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.
Status:
Recruiting
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
Background: Achieving glycemic control without risking hypoglycemia imposes a major challenge
in the management of toddlers and preschool children with Type 1 diabetes(T1D). Optimal
insulin therapy for young children with T1D should provide effective glycemic control while
minimizing the risk of hypoglycemia and hyperglycemia. Despite the advantages of the
basal-bolus insulin regimens, hypoglycemia still presents a major barrier in achieving
desirable glycemic control. Objectives: To compare the effectiveness of insulin degludec to
insulin glargine and NPH in toddlers and preschool children with T1D in terms of glycosylated
hemoglobin(HbA1C) and frequency of hypoglycemic episodes.
Phase:
Phase 4
Details
Lead Sponsor:
Ain Shams University Nouran yousef
Treatments:
Insulin, Isophane Isophane insulin, beef Isophane Insulin, Human